ArticleAmerican journal of respiratory and critical care medicine2026

Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

Damian G Downey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.